Clinical Trial Update: Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

The document reports the completion of a Phase 1/2 clinical trial evaluating autologous dendritic cell therapy for hormone-refractory metastatic prostate cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Autologous dendritic cell therapy (dendritic cells (autologous))

Snippet

Sponsor: Samsung Medical Center | Conditions: Prostatic Cancer | Phase 1, Phase 2 | Status: COMPLETED